Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1404123/000140412321000063/onem-20210630.htm
February 2023
February 2023
November 2022
November 2022
September 2022
September 2022
August 2022
July 2022
July 2022
June 2022
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1404123/000140412321000063/onem-20210630.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by 1Life Healthcare Inc.
1Life Healthcare Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:
Rating
Learn More![]()
In addition, adjusted EBITDA has limitations as an analytical tool, including: 29 although depreciation and amortization are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and adjusted EBITDA does not reflect cash used for capital expenditures for such replacements or for new capital expenditures; adjusted EBITDA does not include the dilution that results from stock-based compensation or any cash outflows included in stock-based compensation, including from our purchases of shares of outstanding common stock; and adjusted EBITDA does not reflect interest expense on our debt or the cash requirements necessary to service interest or principal payments.
As we invest in new markets, in the short term, we expect these activities to increase our operating expenses and cost of care; however, in the long term we anticipate that these investments will positively impact our results of operations.
In markets where we earn patient service revenue, increased visits typically result in higher care margin.
Net Loss Attributable to Noncontrolling Interest Three Months EndedJune 30, Six Months EndedJune 30, 2021 2020 $ Change %Change 2021 2020 $ Change %Change (dollar amounts in thousands) (dollar amounts in thousands) Net loss attributable to noncontrolling interest $ - $ - $ - nm $ - $ (704) $ 704 nm nm - not meaningful The $0.7 million decrease in net loss attributable to noncontrolling interest for the six months ended June 30, 2021 compared to the same period in 2020 was due to the deconsolidation of the joint venture as of April 1, 2020.
Sales and Marketing Sales and marketing expenses consist of employee-related expenses, including salaries and related costs, commissions and stock-based compensation costs for our employees engaged in marketing, sales, account management and sales support.
Cash Flows from Investing Activities...Read more
We expect our general and...Read more
A large portion of these...Read more
In addition, legal and professional...Read more
In addition, legal and professional...Read more
The remainder of the 36...Read more
The remainder of the increase...Read more
27 Key Metrics and Non-GAAP...Read more
For the six months ended...Read more
35 Operating Expenses Cost of...Read more
As a result, as net...Read more
The $33.0 million, or 31%,...Read more
37 Change in Fair Value...Read more
The Merger Agreement contains certain...Read more
We recognize net revenue as...Read more
Beginning in the second half...Read more
In addition, we expanded our...Read more
Our future capital requirements will...Read more
Cash Flows from Financing Activities...Read more
We expect to continue to...Read more
We continue to have significant...Read more
The increases were primarily due...Read more
Cost of care primarily includes...Read more
Depreciation and Amortization Depreciation and...Read more
Depreciation and amortization expenses increased...Read more
We expect to hire additional...Read more
Cost of care, exclusive of...Read more
Cost of care, exclusive of...Read more
We include adjusted EBITDA in...Read more
Membership revenue is recognized ratably...Read more
As we expand to new...Read more
The increase in accounts receivable...Read more
Net patient service revenue increased...Read more
Net patient service revenue increased...Read more
We believe that our ability...Read more
We remeasured the redeemable convertible...Read more
The increases were primarily due...Read more
However, the effects of this...Read more
All partnership revenue is recognized...Read more
Adjusted EBITDA is presented for...Read more
Our definition of adjusted EBITDA...Read more
The healthcare system's share of...Read more
Net patient service and partnership...Read more
Net patient service and partnership...Read more
As we open new offices,...Read more
Effective April 1, 2020, we...Read more
Net revenue increased $85.0 million,...Read more
Membership revenue increased $3.2 million,...Read more
Membership revenue increased $8.2 million,...Read more
These measures and practices reduced...Read more
We believe some of the...Read more
Sales and marketing expenses also...Read more
Pursuant to the terms of...Read more
Partnership revenue increased $22.1 million,...Read more
Partnership revenue increased $47.6 million,...Read more
24 During the first half...Read more
Interest income decreased $1.2 million,...Read more
Our ability to maintain or...Read more
As of June 30, 2021,...Read more
In addition, net revenue per...Read more
The increase in prepaid expenses...Read more
Interest expense increased $3.7 million...Read more
The increase in deferred revenue...Read more
Comparison of the Three and...Read more
The increase in accounts payable...Read more
Interest Expense Interest expense consists...Read more
The following table provides a...Read more
These decreases were due to...Read more
The $0.2 million increase in...Read more
Other companies that present care...Read more
Interest Expense nm - not...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Material Contracts, Statements, Certifications & more
1Life Healthcare Inc provided additional information to their SEC Filing as exhibits
Ticker: ONEM
CIK: 1404123
Form Type: 10-Q Quarterly Report
Accession Number: 0001404123-21-000063
Submitted to the SEC: Wed Aug 04 2021 5:11:24 PM EST
Accepted by the SEC: Wed Aug 04 2021
Period: Wednesday, June 30, 2021
Industry: Offices And Clinics Of Doctors Of Medicine